SUPN

Supernus Pharmaceuticals, Inc. (SUPN) | Rumor.io

Supernus Pharmaceuticals

SUPN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,446

Bullish sentiment (50-day avg)100%

Price to earnings ratio40.7

Market capitalization2.6B

Earnings per share-1.92

Dividend yield (TTM)—

Revenue (annual)719M

Net income (annual)-38.5M

Social

What share of all stock conversation is about SUPN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock transaction, creating a diversified CNS biopharmaceutical company with $2.2 billion in combined revenues.
The merger is expected to generate significant value for stockholders of both companies, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.
Supernus reported Q2 2026 earnings with total revenues of $219.1 million, a 32% increase year-over-year, driven by growth products revenue of $175.7 million, a 52% increase year-over-year.

Generated by AI

Sentiment

Of the messages about SUPN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.59% +5.07
Bearish	—	—	—	4.41% -5.07

Bullish· Aug 16

$SUPN has broken out above $44.95, driven by positive earnings and a target of $49.90.
Supernus Pharmaceuticals, Inc. has received a favorable ruling, providing a boost to the stock.
$SUPN is expected to reach $51, driven by its strong epilepsy franchise, secured cash flows, and significant value potential.

Bearish· Nov 6

$SUPN was downgraded from Buy to Hold at Jefferies with a new price target of $23, a 50% reduction from the previous target of $46.
The company's recent phase III failure and potential NDA submission issues have made it a "short cover" opportunity, but also a high-risk position.
Waning marketed drugs, an ADHD project that may not be better than generics, and a phase III failure have led to a significant price drop, with some investors hoping for a revenge trade at $15.

Generated by AI

Topics

Of the messages about SUPN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	85.84%
Analysts	0%	0%	0%	10.3%
Earnings	0%	0%	0%	1.72%
Technical Analysis	0%	0%	0%	2.15%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Jun 1

Piper Jaffray upgraded Supernus Pharmaceuticals to Overweight with a price target of $44.
The upgrade is based on a possible label expansion for Supernus' seizure drug.
Piper Jaffray raised its price target for Supernus Pharmaceuticals to $45.00 at Jefferies Group LLC.

Announcements· Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock deal, with Supernus shareholders receiving 1.54 Indivior shares for every share they own.
The combined company will have a pro forma net revenue of $2.2 billion and will operate under the name Supernus, Inc., with Jack Khattar remaining as CEO.
The merger is expected to generate significant value for stockholders of both companies, with Supernus stockholders receiving a $1 billion special cash dividend before the deal closes.

Generated by AI

Community

Of the messages about SUPN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	83.33%	60.21%
Newcomers	100%	100%	16.67%	39.79%

Regulars· Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock deal, creating a diversified CNS biopharmaceutical leader with significant scale and expected annual synergies of $125 million.
The combined company is expected to generate significant value for stockholders of both companies, with a pro forma net revenue of $2.2 billion and adjusted EBITDA of $888 million.
The merger is expected to close in the fourth quarter of 2026, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.

Newcomers· Aug 3

Supernus Pharmaceuticals has reported Q2 2026 results with total revenues of $219.1 million, up 32% year over year, driven by combined revenues from four growth products totaling $175.7 million (up 52% YoY).
The company has agreed to merge with Indivior Pharmaceuticals in an all-stock deal, creating a combined CNS biopharmaceutical leader valued at $2.2 billion in combined annual revenues.
The merger is expected to generate $125 million in annual cost savings through the consolidation of the two companies' operations and functions, primarily in the CNS (central nervous system) area.

Generated by AI

Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...

11d agofinance.yahoo.com

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

11d agoYahoo Finance

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

12d agoBarchart.com

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

Indivior Pharmaceuticals (INDV) said Thursday that its board of directors has declared a special cas

12d agoYahoo Finance

Supernus at Wells Fargo conference: growth after patent losses

19d agoInvesting.com

Supernus at cantor global healthcare conference: merger and growth push

20d agoInvesting.com

Also Discussed

Investors talking about SUPN also mention

#	Name	Attention
1	EGRX - Eagle Pharmaceuticals, Inc.	——
2	LeMaitre Vascular Inc.LMAT	0%0
3	Acadia Pharmaceuticals Inc.ACAD	0%+0
4	HZNP - Horizon Therapeutics Public Limited Company	——
5	Klaviyo Inc.KVYO	0%0
6	Invesco BulletShares 2034 Corporate Bond ETFBSCY	0%0
7	ANGI Homeservices IncANGI	0%0
8	Extreme Networks Inc.EXTR	0%new
9	LivaNova PLCLIVN	0%0
10	Global Business Travel Group, Inc.GBTG	0%new

Supernus Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.

Website

Location

9715 Key West Avenue

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about SUPN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock transaction, creating a diversified CNS biopharmaceutical company with $2.2 billion in combined revenues.
The merger is expected to generate significant value for stockholders of both companies, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.
Supernus reported Q2 2026 earnings with total revenues of $219.1 million, a 32% increase year-over-year, driven by growth products revenue of $175.7 million, a 52% increase year-over-year.

Generated by AI

Sentiment

Of the messages about SUPN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.59% +5.07
Bearish	—	—	—	4.41% -5.07

Bullish· Aug 16

$SUPN has broken out above $44.95, driven by positive earnings and a target of $49.90.
Supernus Pharmaceuticals, Inc. has received a favorable ruling, providing a boost to the stock.
$SUPN is expected to reach $51, driven by its strong epilepsy franchise, secured cash flows, and significant value potential.

Bearish· Nov 6

$SUPN was downgraded from Buy to Hold at Jefferies with a new price target of $23, a 50% reduction from the previous target of $46.
The company's recent phase III failure and potential NDA submission issues have made it a "short cover" opportunity, but also a high-risk position.
Waning marketed drugs, an ADHD project that may not be better than generics, and a phase III failure have led to a significant price drop, with some investors hoping for a revenge trade at $15.

Generated by AI

Topics

Of the messages about SUPN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	85.84%
Analysts	0%	0%	0%	10.3%
Earnings	0%	0%	0%	1.72%
Technical Analysis	0%	0%	0%	2.15%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Jun 1

Piper Jaffray upgraded Supernus Pharmaceuticals to Overweight with a price target of $44.
The upgrade is based on a possible label expansion for Supernus' seizure drug.
Piper Jaffray raised its price target for Supernus Pharmaceuticals to $45.00 at Jefferies Group LLC.

Announcements· Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock deal, with Supernus shareholders receiving 1.54 Indivior shares for every share they own.
The combined company will have a pro forma net revenue of $2.2 billion and will operate under the name Supernus, Inc., with Jack Khattar remaining as CEO.
The merger is expected to generate significant value for stockholders of both companies, with Supernus stockholders receiving a $1 billion special cash dividend before the deal closes.

Generated by AI

Community

Of the messages about SUPN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	83.33%	60.21%
Newcomers	100%	100%	16.67%	39.79%

Regulars· Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock deal, creating a diversified CNS biopharmaceutical leader with significant scale and expected annual synergies of $125 million.
The combined company is expected to generate significant value for stockholders of both companies, with a pro forma net revenue of $2.2 billion and adjusted EBITDA of $888 million.
The merger is expected to close in the fourth quarter of 2026, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.

Newcomers· Aug 3

Supernus Pharmaceuticals has reported Q2 2026 results with total revenues of $219.1 million, up 32% year over year, driven by combined revenues from four growth products totaling $175.7 million (up 52% YoY).
The company has agreed to merge with Indivior Pharmaceuticals in an all-stock deal, creating a combined CNS biopharmaceutical leader valued at $2.2 billion in combined annual revenues.
The merger is expected to generate $125 million in annual cost savings through the consolidation of the two companies' operations and functions, primarily in the CNS (central nervous system) area.

Generated by AI

Supernus Pharmaceuticals

Social

Aug 3

Bullish· Aug 16

Bearish· Nov 6

Analysts· Jun 1

Announcements· Aug 3

Regulars· Aug 3

Newcomers· Aug 3

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

Supernus at Wells Fargo conference: growth after patent losses

Supernus at cantor global healthcare conference: merger and growth push

Also Discussed

Supernus Pharmaceuticals, Inc.

Company Information

Location

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

Supernus at Wells Fargo conference: growth after patent losses

Supernus at cantor global healthcare conference: merger and growth push

Also Discussed

Social

Aug 3

Bullish· Aug 16

Bearish· Nov 6

Analysts· Jun 1

Announcements· Aug 3

Regulars· Aug 3

Newcomers· Aug 3